Evolva Holding nets US$13 million in financing from Nice & Green to drive growth
03 Jan 2022 --- Swiss biotech company Evolva Holding has recently signed a contract with the proprietary investment firm Nice & Green. The deal will secure Evolva’s financing lines until the end of 2023.
With the deal, Nice & Green will supply Evolva with additional incremental financing lines to the tune of US$13 million. This is in addition to a since-untapped financing line of US$17.4 million. Evolva will have more than US$30 million available if needed.
Evolva says it may use the finances in quarterly tranches. The said funds are intended to support commercial activities and product launches, expand and streamline the manufacturing process and fund further product pipeline developments.
Nice & Green has provided funding to Evolva in the past.The money may provide relief to the company that, despite record order intakes last year, happened to struggle with supply-chain constraints resulting from the COVID-19 pandemic.
Evolva may also repay the funds in the form of company shares or cash.
Evolva and Nice & Green
Nice & Green is a proprietary investment and corporate financing firm based in Switzerland. The company specializes in supporting small to medium-sized businesses. Nice & Green has supplied Evolva with funding in the past; in 2020, the company freed up over US$13 million in financing for Evolva.
Evolva is a Switzerland-based biotechnology company specializing in the research, development and commercialization of natural products. It has developed nutraceuticals and cosmeceuticals such as L-arabinose and resveratrol in the past.
Last year, PersonalCareInsights interviewed Evolva’s senior technical manager of health ingredients, Marcia da Silva Pinto about resveratrol, as well as the ingestible beauty trend. According to her, this trend has dramatically expanded under the COVID-19 pandemic.
Edited by Olivia Nelson
